Similar articles

• [Clinical study of Hodgkin's disease after 25 years].

  Dienstbier Z, Skala E, Blomannová E. Dienstbier Z, et al. Cas Lek Cesk. 2004;143(3):184-6. Cas Lek Cesk. 2004. PMID: 15134038 Czech.
• Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group.

  Meyer RM, Gospodarowicz MK, Connors JM, Pearcey RG, Bezjak A, Wells WA, Burns BF, Winter JN, Horning SJ, Dar AR, Djurfeldt MS, Ding K, Shepherd LE; National Cancer Institute of Canada Clinical Trials Group; Eastern Cooperative Oncology Group. Meyer RM, et al. J Clin Oncol. 2005 Jul 20;23(21):4634-42. doi: 10.1200/JCO.2005.09.085. Epub 2005 Apr 18. J Clin Oncol. 2005. PMID: 15837968 Clinical Trial.
• Long-term results of autologous stem cell transplantation for Hodgkin's disease (HD) and low-/intermediate-grade B non-Hodgkin's lymphoma (NHL): a report from the Austrian Stem Cell Transplantation Registry (ASCTR).

  Nachbaur D, Greinix HT, Koller E, Krieger O, Linkesch W, Kasparu H, Pober M, Hinterberger W, Hausmaninger H, Heistinger M, Ulsperger E, Karlhuber S, Schwinger W, Lindner B. Nachbaur D, et al. Ann Hematol. 2005 Jul;84(7):462-73. doi: 10.1007/s00277-004-1003-3. Epub 2005 Feb 23. Ann Hematol. 2005. PMID: 15726362
• Studying survival in Hodgkin's lymphoma: all for one, or one for all? Why methodology matters.

  Smith SD, Sweetenham JW. Smith SD, et al. Oncologist. 2009 Aug;14(8):814-5. doi: 10.1634/theoncologist.2009-0128. Epub 2009 Jul 31. Oncologist. 2009. PMID: 19648313 Review. No abstract available.
• Targeting cellular FLICE-like inhibitory protein as a novel approach to the treatment of Hodgkin's lymphoma.

  Dutton A, Burns AT, Young LS, Murray PG. Dutton A, et al. Expert Rev Anticancer Ther. 2006 Jun;6(6):911-9. doi: 10.1586/14737140.6.6.911. Expert Rev Anticancer Ther. 2006. PMID: 16761935 Review.